-
公开(公告)号：US5925537A
公开(公告)日：1999-07-20
申请号：US982260
申请日：1997-12-01
CPC分类号： C12R1/01 , C07J17/005 , C12P33/00
摘要： According to this invention, Prevotella sp. S-1 strain (Bacteroidaceae family, KFCC-10923) is cultured in a medium supplemented with Panax ginseng saponin so as to collect the metabolites of saponin generated and accumulated in the medium, thus ensuring their selective production with high efficiency.This invention related to a process for the preparation of the metabolites of protopanaxadiol saponin, wherein Prevotella sp. S-1 strain (Bacteroidaceae family, KFCC-10923), is cultured at a medium supplemented with Panax ginseng saponin and then, the metabolites of protopanaxadiol saponin contained in the medium--20-O-.beta.-D-glucopyranosyl-20(s)-protopanaxadiol, 20-O-�.alpha.-L-arabinopyranosyl-20(s)-protopanaxadiol, and 20-0-�.alpha.-L-arabinopuranosyl(1.fwdarw.6)-.beta.-D-glucopyranosyl!-20(s)-protopanaxadiol --are generated and accumulated for collecting them thereof.
摘要翻译： 根据本发明，Prevotella sp。 将S-1菌株（菌型科，KFCC-10923）在补充有人参皂苷的培养基中培养，以收集培养基中生成和积累的皂苷的代谢物，从而确保其高效选择性生产。 本发明涉及一种制备原人参二醇皂苷代谢物的方法，其中Prevotella sp。 在补充有人参皂苷的培养基中培养S-1菌株（菌型科，KFCC-10923），然后将中-20-β-D-吡喃葡萄糖基-20（s）中所含的原人参二醇皂苷的代谢物， - 原丙酰基二醇，20-O- [α-L-阿拉伯吡喃糖基-20（s） - 原人参二醇和20-0- [α-L-阿拉伯呋喃糖基（1-> 6）-β-D-吡喃葡萄糖基] -20（s） 产生并积累，以收集它们。
-
2.发明授权Metabolites of ginseng saponins by human intestinal bacteria and its preparation for an anticancer 失效人类皂角蛋白的人体代谢物由人肠道细菌及其抗癌剂的制备
公开(公告)号：US5919770A
公开(公告)日：1999-07-06
申请号：US945422
申请日：1997-10-22
CPC分类号： C07J17/005
摘要： This invention relates to ginsenoside Mc with formula (I), ##STR1## an intestinal flora metabolite of ginseng saponin and anticancer agent containing it as an active ingredient. In addition to a novel compound, the anticancer agent of this invention consists of one active ingredient elected from compound K, compound Y or 20(S)-protopanaxatriol, intestinal flora metabolites of ginseng saponin, together with one or more pharmaceutically acceptable carriers. Said agent is a novel type of potential anticancer agent since it has immunopotentiating actions including inhibitory actions on the vascularization of tumors and extravasation of cancer cells.
摘要翻译： PCT No.PCT / KR96 / 00281 Sec。 371日期1997年10月22日第 102（e）1997年10月22日PCT PCT 1996年12月31日PCT公布。 公开号WO97 / 31013 日期：1997年8月28日本发明涉及人参皂苷的肠道菌群代谢物和含有它作为活性成分的抗癌剂的式（I）的人参皂苷Mc。 除了新型化合物之外，本发明的抗癌剂还包括选自化合物K，化合物Y或20（S） - 原人参三醇，人参皂苷的肠道菌群代谢物，以及一种或多种药学上可接受的载体的一种活性成分。 所述药剂是一种新型的潜在抗癌剂，因为其具有免疫增强作用，包括对肿瘤血管形成和癌细胞外渗的抑制作用。
-
公开(公告)号：US20130157360A1
公开(公告)日：2013-06-20
申请号：US13806225
申请日：2011-06-24
申请人： John C. March , Jiajie Yu , Jong Hwan Sung
发明人： John C. March , Jiajie Yu , Jong Hwan Sung
IPC分类号： A61L27/14
CPC分类号： A61L27/14 , B29C33/3857 , B29C33/424 , B29K2083/00
摘要： Three-dimensional biomimetic tissue scaffolds, as well as methods of manufacture of these scaffolds. The method is fully customizable to create a biomimetic tissue scaffold with shapes, densities, and geometries similar or identical to the tissue it imitates. For example, physiologically realistic collagen/PEG villi created using the method are designed to have a high-aspect ratio and curvature similar to villi found in the human small intestine. Accordingly, the biomimetic tissue scaffolds serve as an improved in vitro model for a wide variety of physiological research, as well as pharmacological testing and drug, compound, and/or metabolite uptake by cells growing on the scaffold, among many other uses.
摘要翻译： 三维仿生组织支架，以及这些支架的制造方法。 该方法是完全可定制的，以创建与其模拟的组织类似或相同的形状，密度和几何形状的仿生组织支架。 例如，使用该方法产生的生理学上现实的胶原蛋白/ PEG绒毛被设计成具有与人类小肠中发现的绒毛相似的高纵横比和曲率。 因此，仿生组织支架用作多种生理研究的改进的体外模型，以及许多其它用途中生长在支架上的细胞的药理学测试和药物，化合物和/或代谢物摄取。
-
公开(公告)号：US08574639B2
公开(公告)日：2013-11-05
申请号：US12857707
申请日：2010-08-17
申请人： David C. Konn , Dae Keun Sim , Jong Hwan Sung , Seung Kwon Lee , Min Goo Cho
发明人： David C. Konn , Dae Keun Sim , Jong Hwan Sung , Seung Kwon Lee , Min Goo Cho
CPC分类号： A61K36/258 , A61K2300/00
摘要： The present invention relates to a method for preparing a fermented ginseng concentrate. The method first involves subjecting ginseng to an extraction with a solvent to obtain a ginseng extract. Next, pectinase and beta-galactosidase are added to the ginseng extract under conditions effective to ferment the ginseng extract. The fermented extract is then concentrated to produce a fermented ginseng concentrate. The method may further involve drying the fermented ginseng concentrate to obtain fermented ginseng powder. Combinations of the invention ginseng materials with other active and/or inactive materials are also disclosed.
摘要翻译： 本发明涉及一种制备发酵人参精矿的方法。 该方法首先包括使人参进行溶剂萃取以获得人参提取物。 接下来，在有效发酵人参提取物的条件下，将果胶酶和β-半乳糖苷酶加入到人参提取物中。 然后将发酵的提取物浓缩以产生发酵的人参浓缩物。 该方法还可以包括干燥发酵人参浓缩物以获得发酵人参粉末。 还公开了本发明人参材料与其它活性和/或不活泼材料的组合。
-
公开(公告)号：US20120045428A1
公开(公告)日：2012-02-23
申请号：US12857707
申请日：2010-08-17
申请人： David C. KONN , Dae Keun Sim , Jong Hwan Sung , Seung Kwon Lee , Min Goo Cho
发明人： David C. KONN , Dae Keun Sim , Jong Hwan Sung , Seung Kwon Lee , Min Goo Cho
CPC分类号： A61K36/258 , A61K2300/00
摘要： The present invention relates to a method for preparing a fermented ginseng concentrate. The method first involves subjecting ginseng to an extraction with a solvent to obtain a ginseng extract. Next, pectinase and beta-galactosidase are added to the ginseng extract under conditions effective to ferment the ginseng extract. The fermented extract is then concentrated to produce a fermented ginseng concentrate. The method may further involve drying the fermented ginseng concentrate to obtain fermented ginseng powder. Combinations of the invention ginseng materials with other active and/or inactive materials are also disclosed.
摘要翻译： 本发明涉及一种制备发酵人参精矿的方法。 该方法首先包括使人参进行溶剂萃取以获得人参提取物。 接下来，在有效发酵人参提取物的条件下，将果胶酶和β-半乳糖苷酶加入到人参提取物中。 然后将发酵的提取物浓缩以产生发酵的人参浓缩物。 该方法还可以包括干燥发酵人参浓缩物以获得发酵人参粉末。 还公开了本发明人参材料与其它活性和/或不活泼材料的组合。
-
6.发明授权Microfluidic device for pharmacokinetic-pharmacodynamic study of drugs and uses thereof 有权用于药物的药代动力学 - 药效学研究的微流控装置及其用途公开(公告)号：US08748180B2
公开(公告)日：2014-06-10
申请号：US13387585
申请日：2010-07-29
申请人： Michael L. Shuler , Jong Hwan Sung
发明人： Michael L. Shuler , Jong Hwan Sung
CPC分类号： G01N33/5008 , C12M21/08 , C12M23/12 , C12M23/16 , C12M29/00 , G01N33/5014 , G01N2500/10
摘要： A microfluidic device for culturing cells, termed a microscale cell culture analog (μCCA), is provided. The microfluidic device allows multiple cell or tissue types to be cultured in a physiologically relevant environment, facilitates high-throughput operation and can be used for drug discovery. The microfluidic device uses gravity-induced fluidic flow, eliminating the need for a pump and preventing formation of air bubbles. Reciprocating motion between a pair of connected reservoirs is used to effect the gravity-induced flow in microfluidic channels. Bacterial contamination is reduced and high throughput enabled by eliminating a pump. The microfluidic device integrates a pharmacokinetic-pharmacodynamic (PK-PD) model to enable PK-PD analyses on-chip. This combined in vitro/in silico system enables prediction of drug toxicity in a more realistic manner than conventional in vitro systems.
摘要翻译： 提供了称为微量细胞培养物类似物（μCCA）的用于培养细胞的微流体装置。 微流体装置允许在生理相关环境中培养多种细胞或组织类型，促进高通量操作并且可用于药物发现。 微流体装置使用重力引起的流体流动，不需要泵并防止形成气泡。 使用一对连接的储存器之间的往复运动来实现微流体通道中的重力引起的流动。 细菌污染减少，消除泵的吞吐量高。 微流控装置集成了药代动力学 - 药效学（PK-PD）模型，以实现片上PK-PD分析。 这种体外/计算机系统的组合能够以比现有体外系统更现实的方式预测药物毒性。
-
公开(公告)号：US08541035B2
公开(公告)日：2013-09-24
申请号：US12466093
申请日：2009-05-14
申请人： Dae Keun Sim , Jong Hwan Sung , Seung Kwon Lee , Min Goo Cho
发明人： Dae Keun Sim , Jong Hwan Sung , Seung Kwon Lee , Min Goo Cho
CPC分类号： A61K36/258 , A23L33/105
摘要： The present invention relates to a method for preparing a fermented ginseng concentrate. The method first involves subjecting ginseng to an extraction with a solvent to obtain a ginseng extract. Next, pectinase and beta-galactosidase are added to the ginseng extract under conditions effective to ferment the ginseng extract. The fermented extract is then concentrated to produce a fermented ginseng concentrate. The method may further involve drying the fermented ginseng concentrate to obtain fermented ginseng powder.
摘要翻译： 本发明涉及一种制备发酵人参精矿的方法。 该方法首先包括使人参进行溶剂萃取以获得人参提取物。 接下来，在有效发酵人参提取物的条件下，将果胶酶和β-半乳糖苷酶加入到人参提取物中。 然后将发酵的提取物浓缩以产生发酵的人参浓缩物。 该方法还可以包括干燥发酵人参浓缩物以获得发酵人参粉末。
-
8.发明申请MICROFLUIDIC DEVICE FOR PHARMACOKINETIC-PHARMACODYNAMIC STUDY OF DRUGS AND USES THEREOF 有权药物动力学药理动力学研究的微流体装置及其用途公开(公告)号：US20120135452A1
公开(公告)日：2012-05-31
申请号：US13387585
申请日：2010-07-29
申请人： Michael L. Shuler , Jong Hwan Sung
发明人： Michael L. Shuler , Jong Hwan Sung
CPC分类号： G01N33/5008 , C12M21/08 , C12M23/12 , C12M23/16 , C12M29/00 , G01N33/5014 , G01N2500/10
摘要： A microfluidic device for culturing cells, termed a microscale cell culture analog (μCCA), is provided. The microfluidic device allows multiple cell or tissue types to be cultured in a physiologically relevant environment, facilitates high-throughput operation and can be used for drug discovery. The microfluidic device uses gravity-induced fluidic flow, eliminating the need for a pump and preventing formation of air bubbles. Reciprocating motion between a pair of connected reservoirs is used to effect the gravity-induced flow in microfluidic channels. Bacterial contamination is reduced and high throughput enabled by eliminating a pump. The microfluidic device integrates a pharmacokinetic-pharmacodynamic (PK-PD) model to enable PK-PD analyses on-chip. This combined in vitro/in silico system enables prediction of drug toxicity in a more realistic manner than conventional in vitro systems.
摘要翻译： 提供了称为微量细胞培养物类似物（μCCA）的用于培养细胞的微流体装置。 微流体装置允许在生理相关环境中培养多种细胞或组织类型，促进高通量操作并且可用于药物发现。 微流体装置使用重力引起的流体流动，不需要泵并防止形成气泡。 使用一对连接的储存器之间的往复运动来实现微流体通道中的重力引起的流动。 细菌污染减少，消除泵的吞吐量高。 微流控装置集成了药代动力学 - 药效学（PK-PD）模型，以实现片上PK-PD分析。 这种体外/计算机系统的组合能够以比现有体外系统更现实的方式预测药物毒性。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.031 秒)
